NCT05799157

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 153 (actual)
• Sponsor: Veradermics, Inc. · Industry
• Sex: All
• Age: 9 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris

Detailed description

Protocol 250-12951-201 is a planned Phase 2 study entitled "A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with Verruca Vulgaris". Eligible subjects will be randomized into one of the three treatment groups (high dose, low dose, vehicle).

Conditions

• Verruca Vulgaris
• Warts
• Common Wart

Interventions

Type	Name	Description
DRUG	VDMN-21 Patch Low Dose	Microneedle patch containing 125 mcg of active drug
DRUG	VDMN-21 Patch High Dose	Microneedle patch containing 250 mcg of active drug
DRUG	Vehicle Patch	Placebo microneedle patch containing no active drug (i.e., placebo)

Timeline

• Start date: 2023-02-28
• Primary completion: 2025-02-25
• Completion: 2025-02-25
• First posted: 2023-04-05
• Last updated: 2025-05-08

Locations

16 sites across 1 country: United States

Regulatory

• FDA-regulated drug study